The bio industry is one of the next 10 promising technologies!
It is regarded as a key industry in the 21st century that contributes to a healthy abundant life.

  • The 21st-century bioindustry has been recognized as a key industry that contributes to the health and abundance of humanity based on long-term research and understanding. In particular, microbiome-related biotechnology requires a high degree of expertise and is drawing great attention as it was selected as a next-generation promising technology among all industrial fields by the Science and World Economic Forum in 2014.

    Kobiolabs has been publishing a number of Korean and international patents and studies in various fields including microbiome analysis, probiotics, and microbiome treatment technology, receiving recognition for its global technological capabilities. In particular, our researchers (including me) have joined the International Human Microbiome Consortium (IHMC) to represent Korea.
  • We have collaborated with Data Analysis and Coordination Center for the U.S.’ Human Microbiome Project, and our microbiome analysis technology has received international recognition.

    We will continue striving to realize our research achievements with top experts in the fields into the valuable asset of society to ensure that everyone enjoys a healthy happy life.

    Thank you.
    • President & CEO

GwangPyo Ko



1988 - 1992
B.S. in Microbiology. Seoul National University (SNU), Seoul, Korea
1992 - 1994
M.S. in Microbiology. SNU
1994 - 1996
M.S. in Environmental Health. Harvard University,Boston,MA,USA
1996 - 2000
Sc.D. in Environmental Health Microbiology. Harvard University

Academic Experiences

2001 - 2003
Postdoctoral fellow. University of North Carolina Chapel Hill, NC, USA
2003 - 2005
Assistant Professor. Dept. of Environmental Health, University of Texas Health Science Center at Houston
2005 - Present
Professor of Environmental Health Microbiology. SNU
2011 - 2012
Visiting Scientist. Broad Institute of MIT and Harvard

Professional Services

2011 - Present
Director. Center for Human and Environmental Microbiome, SNU
2011 - Present
PI & Board Member. International Human Microbiome Consortium (IHMC)
2010 - Present
Editorial Board. Scientific Reports (Nature Publishing Group); Journal of Microbiology; Journal of Microbiology and Biotechnology; Journal of Environmental Health Sciences
Member. LMO Public health safety professional committee, Korea CDC
Board member. Foundation of Korean Public Health
Chief Scientific Advisor in Microbial Risk Assessment, and Waterborne Virus,
National Institute of Environmental Research (NIER)
Member of Scientific Review Committee. National Research Foundation of Korea
Member of Scientific Advisory Committee. Korean Food and Drug Administration

Cheolwon Park



1991 - 1995
B.S. in Pharmacy. SNU
1995 - 1997
M.S. in Medicinal Chemistry. SNU

Work Experiences

1997 - 2007
R&D. Business Development, Corporate Strategy
2007 – 2013
CJ CHEILJEDANG, Pharmaceuticals BU
Team Leader. Business Development & Corporate Strategy
2013 – 2014
Head. R&D Center
2014 – 2017
Head. R&D in Alvogen Korea
Head. Portfolio & BD in Alvogen Asia Pacific

Tae-Wook Nam

CTO(Research Director)


1994 – 1998
B.S. in Microbiology. SNU
1998 – 2000
M.S. in Microbiology. SNU
2000 – 2005
Ph.D. in Microbiology. SNU

Work Experiences

2005 – 2006
Post-doctoral Fellow. Institute of Microbiology. SNU
2006 – 2007
Research Scientist. Polar BioCenter, Korea Polar Research Institute, KORDI
2007 – 2012
Research Associate Bacteriology. University of Wisconsin-Madison
(Director of Great Lake Bioenergy Research Institute)
2012 – 2014
Research Staff. Samsung Advanced Institute of Technology, Samsung Electronics
2014 – 2017
Director. NGS Service Division, Macrogen, Inc.


Business Philosophy

Management Goals

Human Resources
and Organization

  • Passion
  • Diversity and autonomy in the
    organization allow employees’ creativity
    and the realization of their passions.
  • Providing opportunities for happy life and realizing dreams, developing products for customers to enjoy happy healthy lives, and striving to provide high investment return for our investors.

Mission (3p)

Passion Persistence Partnership

Personnel and

- Our company guarantees diversity and autonomy
- Our company will strive to create an atmosphere where employees can exercise their creative thinking and passio


- To Provide a comfortable and fulfilling atmos-phere for our employees to develop their skills
- To develop useful products for the healty living of our clients
- To offer our best efforts and high returns for our investors

  • Company Logo

    The leaf in the logo symbolizes life and nature. The circle around the leaf represents the microbiome with beneficial interactions in the human body and the environment

  • May 2018

    Selected as a Research and Business Development (R&BD) project by the Ministry of Trade, Industry, and Energy

    Received the Ministry of Science and ICT Award

    Selected as a Military Service Business by the Ministry of National Defense

  • July 2017

    Registered as a participant in MIT-lTP

    Innovative Technology Development Project of the Small

    and Medium Business Administration

    July 2017

    Series B

    Securing ₩10 billion won investment

    (Atinum Investment, Company K, and Stonebridge)

    Selected as a core technology development business by the Ministry of Trade, Industry, and Energy

    June 2017

    Innovative Technology Development Project of the Small and Medium Business Administration

    Selected as a global technology innovation IP strategic development business by the Korea Intellectual Property Strategy Agency

  • September 2016

    Partnership MOU between Kobiolabs and CKD Bio

    Selected as an investment-linked business growth R&D support project by the Ministry of Science, ICT, and Future Planning

    July 2016

    Selected as an immunity mechanism control technology by the Ministry of Science, ICT, and Future Planning

    March 2016

    Series A

    Investment promotion (CKD start-up investment)

    Selected as an IP R&D strategic development business by Korea Intellectual Property Strategy Agency

  • September 2015

    Selected for the high value-added food technology development project by the Ministry of Agriculture, Food, and Rural Affairs

    August 2015

    Secured the investment of Seoul Techno Holdings Inc.

    Selected as an investment-linked mentoring business by the Small and Medium Business Administration

    Certified by the Ministry of Environment as a Virus Inspection Agency

    Selected as a venture business start-up support business by the Small and Medium Business Administration

    July 2015

    Technology transfer MOU with Seoul National University Industry–Academy Cooperation Foundation

    June 2015

    Selected as a Research Exchange and International Industry Development Support Business by the Ministry of Science, ICT, and Future Planning

    May 2015

    Established a Kobiolabs affiliated research institute

    (Center for Microbiome Therapeutics; approved by the Korea Industrial Technology Association)

    Selected as the Research Achievement Commercialization Support Project by the Ministry of Science, ICT, and Future Planning

  • November 2014

    Certified by Kibo Technology Fund as a venture business

    August 2014

    Founded Kobiolabs, Inc.

  • Name
  • Cheolwon Park
  • Tae-wook Nam
  • Sungji Kim
  • Hwang Sang ho
  • June-chul Lee
  • Lee, Jin-woo
  • SungJun Park
  • Department
  • -
  • Center for Microbiome Therapeutics
  • Product development Department
  • Marketing Department
  • Immuno- Pharmacology Department
  • Functional Microorganism Research Team
  • Planning Team
  • Position
  • COO
  • CTO
  • Director
  • Director
  • Director
  • Manager
  • Manager
  • Final education
  • M.S. in Medicinal Chemistry. SNU
  • Ph.D. in Microbiology. SNU
  • M.S. in Medicinal Chemistry. SNU
  • B.S. in Biochemistry. KU
  • Ph.D. in Immunology. SNU
  • Ph.D. in Microbiology. CBNU
  • Ph.D. in Microbiology. SNU
  • Major Career and Duties
  • Alvogen R&D/BD
  • Director. NGS Service Division, Macrogen, Inc.
  • Director. JW pharmaceutical
  • Responsible Researcher. Cell Biotech
  • R&D
  • Research Planning